Replimune Group Inc operates under a business model focused on developing and commercializing oncolytic immunotherapies for the treatment of cancer. The company's innovative approach involves the use of its proprietary platform, called Immulytic™, which is designed to enhance the body's immune response against tumors. Replimune's therapies are aimed at both solid tumors and hematologic malignancies, with a focus on providing patients with a potentially transformative treatment option. By leveraging its deep understanding of immunology and expertise in viral-based therapeutics, Replimune Group Inc strives to make a significant impact in the fight against cancer.

Replimune Group Inc primarily operates in the biotechnology industry.

The main competitors of Replimune Group Inc in the market are established pharmaceutical companies with a focus on developing oncolytic immunotherapies. These competitors include leading players in the biotechnology sector such as Amgen, Inc., Merck & Co., Inc., and Bristol Myers Squibb Company. Replimune Group Inc, a clinical-stage biotechnology company, aims to leverage its innovative immuno-oncology platform to develop next-generation cancer treatments. With its unique portfolio and cutting-edge technologies, Replimune Group Inc strives to distinguish itself among its industry counterparts and contribute to advancements in the field of oncolytic immunotherapies.

Replimune Group Inc is a pioneering biotechnology company focused on developing innovative cancer therapeutics. Founded in 2015, Replimune is dedicated to harnessing the power of oncolytic immunotherapies to treat a wide range of solid tumors. The company's novel approach involves engineering a specific virus to selectively replicate and destroy cancer cells while stimulating the immune response. Replimune's groundbreaking technology, known as Immulytic™, has shown promising results in early-stage clinical trials for various cancers. With a strong commitment to advancing patient care and improving outcomes, Replimune Group Inc is poised to make significant contributions to the field of cancer treatment.

Replimune Group Inc has achieved numerous significant milestones. The company successfully completed its initial public offering (IPO) in July 2018, raising funds to support its research and development activities. In September 2019, Replimune reported positive preliminary data from its Phase 1 clinical trials of RP1 in combination with nivolumab for advanced solid tumors. Later, in May 2020, the company announced positive overall survival data from the Phase 2 portion of the same trial. Replimune also received Fast Track designation from the U.S. FDA for RP1 in advanced cutaneous squamous cell carcinoma. These milestones demonstrate the company's progress, innovation, and potential for future growth.

Replimune Group Inc is primarily present in the United States.

Replimune Group Inc represents values of innovation, integrity, and patient-centricity. With a strong corporate philosophy, they focus on developing oncolytic immunotherapies to combat cancer. The company is dedicated to advancing cutting-edge science and technology to provide effective and transformative treatments for patients. Replimune Group Inc strives to deliver innovative solutions that address unmet medical needs and improve the quality of life for cancer patients. Emphasizing collaboration, they work closely with industry partners and medical professionals to advance their research and impact the lives of millions affected by cancer.

Analysts currently set an average price target of 12,82 USD for the Replimune Group stock (median: 12,24 USD), implying +137,0 % versus the latest price. The consensus is based on 14 analyst ratings.

Replimune Group Analyytikkojen kursstavoitteet 2026

14 analysts currently rate the Replimune Group stock: 11 recommend buying, 3 holding and 0 selling.

Replimune Group Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Replimune Group share trades at 4,51 EUR (5,20 USD).

The Replimune Group share (REPL) is listed on 3 stock exchanges, including: NASDAQ (REPL), Frankfurt (7R8.F), München (7R8.MU).

Replimune Group Inc is a biopharmaceutical company specializing in the development of cell-based therapies for the treatment of cancer. The business model of Replimune Group is based on the development and commercialization of therapy products based on the technology of oncolytic viruses. This technology uses viruses that have been developed to infect and destroy tumor cells. Replimune Group has several products in its portfolio that are based on the fundamental technology of oncolytic viruses. These products are designed to enhance the body's immune response to tumor cells and directly destroy tumor cells. Replimune Group's products are targeted at a wide range of patients suffering from various types of cancer. Replimune Group operates its business activities in various divisions, including research and development, clinical trials, and marketing. The company has a strong research and development department that constantly develops new technologies and products to improve the quality and efficacy of its products. The company also conducts clinical trials to evaluate the efficacy of its products and ensure their safety. Through these studies, the company can also improve and optimize its products to provide better treatment for patients. The marketing of Replimune Group's products is done through the establishment of partnerships with other companies in the biotechnology and pharmaceutical sectors, as well as through direct marketing to hospitals and medical facilities. The company also has a sales department that focuses on marketing its products to oncologists, hematologists, and other specialists. Replimune Group has achieved a strong position in the field of oncolytic viruses in recent years and has become one of the leading companies in this field. According to estimates by the company, the market for oncolytic viruses is expected to grow exponentially in the coming years, providing Replimune Group with an excellent opportunity to further market and expand its products. Overall, the business model of Replimune Group Inc is focused on the development and marketing of products for the treatment of cancer based on the technology of oncolytic viruses. The company operates its business activities in various divisions, including research and development, clinical trials, and marketing. With this strategy, the company has achieved a strong position in the biotechnology and pharmaceutical sectors and has a promising future in oncology research and development.

Liikevaihtoa ei voida laskea Replimune Group:lle tällä hetkellä.

voitto Replimune Group on −313,94 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Replimune Group:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,54. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Replimune Group-osakkeen arvostusta.

P/S-suhdetta ei voida laskea Replimune Group:lle tällä hetkellä.

Replimune Group:n Eulpool-laatuscore on 2/10.

Replimune Group:n ISIN on US76029N1063. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Replimune Group:n WKN on A2JQN1. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Replimune Group:n ticker on REPL. Tämä pörssinoteeraus käytetään Replimune Group-osakkeiden kauppaan pörssissä.

Replimune Group maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Replimune Group kuuluu sektoriin 'Terveydenhuolto'.

Replimune Group:n osingot jaetaan valuutassa USD.